N.Y. Comp. Codes R. & Regs. tit. 9 § 130.22

Current through Register Vol. 46, No. 51, December 18, 2024

Section 130.22 - Testing of Cannabis Product and Medical Cannabis

(a) All testing of samples provided by a laboratory sampling firm to a cannabis laboratory shall be conducted by a cannabis laboratory employing methods approved by the Office and shall:

(1) be within the scope listed on the laboratory's current permit or on any appendices thereto; and

(2) require the prior completion of a demonstration of capability conducted at the same site where samples were prepared or analyzed using an approved method.

(b) Testing of the phytocannabinoid profile in cannabis product and or medical cannabis and any other intermediates or forms shall include, at a minimum, the analyte or groups of analytes specified under this Part.

(c) Testing for analytes or contaminants in cannabis product or medical cannabis, and any other intermediates or forms shall include, but not be limited to, microorganisms, foreign material, metals, moisture content and water activity, mycotoxins, pesticides, residual solvents, terpenoids, and any other analyte or group of analytes determined by the Office, consistent with the acceptable limits determined by the Office for each of the foregoing.

(d) The Office shall make available a list of required analytes, their acceptable limits and approved testing methods on the Office's website and in any other manner as determined by the Board.

N.Y. Comp. Codes R. & Regs. Tit. 9 § 130.22

Adopted New York State Register March 22, 2023/Volume XLV, Issue 12, eff. 3/22/2023